Semi-Annual Review Of The First North 25 Index - The New Portfolio Of The First North 25 Index Will Become Effective On July 2, 2018

Nasdaq (Nasdaq:NDAQ) announces today the results of the semi-annual review of the First North 25 Index (Nasdaq Stockholm: FN25) which will become effective with the market open on Monday, July 2, 2018.

Cibus Nordic Real Estate AB (CIBUS), HRC World Plc (HRC), Infant Bacterial Therapeutics (IBT B), Kvika banki hf. (KVIKA), Sedana Medical AB (SEDANA), Stillfront Group AB (SF) and Vostok Emerging Finance Ltd (VEMF SDB) will be added to the portfolio and Cognosec AB (COGS), IRLAB Therapeutics AB ser. A (IRLAB A) and Prime Living AB (PRIME) will exit the portfolio.

The FN25 consists of the largest and most traded shares listed on Nasdaq First North. Companies included in the FN25 are selected through a two-step process as follows:

The 30 largest companies measured by market capitalization are selected.
The 25 most traded shares within this pool, measured by aggregated trading turnover over a six month period, are selected for the index.

FN25 is reviewed semi-annually in January and July.

The First North 25 Index constituents effective July 2, 2018 are:

Aspire Global plc	Magnolia Bostad AB
BIMobject AB	Next Games Oyj
Cibus Nordic Real Estate AB	Nordic Leisure AB
Cinnober Financial Technology	Paradox Interactive AB
Climeon AB ser. B	PowerCell Sweden AB
Detection Technology Oyj	SaltX Technology Holding AB ser. B
Fastighets AB Trianon ser. B	Samhällsbyggnadsbolaget i Norden AB ser. B
Global Gaming 555 AB	Sedana Medical AB
GomSpace Group AB	Stillfront Group AB
HRC World Plc	THQ Nordic AB ser. B
Infant Bacterial Therapeutics AB ser. B	Verkkokauppa.com Oyj
Kambi Group plc	Vostok Emerging Finance Ltd
Kvika banki hf.